Several real-world datasets have been published evaluating the benefits and risks of dabigatran. In a nationwide Danish registry study, 4,978 incident dabigatran users were propensity matched to 8,936 users of warfarin.3 Rates for stroke, peripheral embolism, and major bleeding were similar for dabigatran and warfarin. However, mortality, intracranial bleeding, and MI events were lower with dabigatran. The unadjusted hazard ratio (HR) for MI for dabigatran 110 mg bid vs warfarin was 0.60 (95% CI, 0.33-1.02) and for dabigatran 150 mg bid vs warfarin, 0.62 (95% CI, 0.30-1.14). The largest study on dabigatran 150 mg was published by the US Food and Drug Administration,4 which collected data from > 134,000 Medicare patients treated with dabigatran for stroke prevention in AF. Dabigatran compared with warfarin significantly reduced the risk of stroke (HR, 0.80; 95% CI, 0.67-0.96), intracranial bleeding (HR, 0.34; 95% CI, 0.26-0.46), and mortality (HR, 0.86; 95% CI, 0.77-0.96). Of particular note, there were numerically fewer MIs in patients taking dabigatran than in those taking warfarin (HR, 0.92; 95% CI, 0.78-1.08).